Proceedings - Boulder Peptide Foundation

BPS 2016

CR845, A Novel Peripherally Acting Kappa Opioid Receptor Agonist for the Treatment of Pain and Pruritus

Stephen O’Connor

Senior Director, Chemistry Research and CMC, Cara Therapeutics, Inc.

ABSTRACT

Peptides with high affinity and selectivity for the kappa opioid receptor have been known for more than 20 years, but peptides suitable for clinical development have not been forthcoming. CR845 is a potent and selective synthetic peptide kappa opioid receptor (KOR) agonist being developed as both intravenous (IV) and oral formulations (enteric-coated tablets). CR845 is currently in mid- to late stage clinical development (Phase 2-3) to assess the safety and efficacy of this drug in patients with post-operative pain, osteoarthritis or uremic pruritus using the IV or oral formulation depending upon the particular indication. CR845 has full agonist activity at rodent and human kappa opioid receptors (EC50 = 0.16 nM) with no other detectable off-target activities. Non-clinical pharmacological studies indicate that CR845 has combined analgesic, antipruritic, and anti-inflammatory properties which support the therapeutic indications of pain and pruritus being pursued with this compound. CR845 is composed of 5 unnatural amino acids and does not readily cross the blood-brain barrier. Consequently, CR845 predominantly activates KORs expressed in peripheral neurons and on immune cells. CR845 is primarily excreted unchanged into the urine and bile with no major metabolites identified. The safety data available to-date and the potential benefit of CR845 treatment support continued study and development of this compound.

BIO

I have been with Cara Therapeutics for 9 years primarily focused on the GMP manufacturing of CR845 drug substance and drug product for the clinical development program. Prior to Cara, I was at Bayer (in West Haven, CT) for 8 years working in both the research (Medicinal Chemistry) and Development (Project Management). I began my professional career with Abbott Laboratories as a Medicinal Chemist in 1993.

Oral Presentations in Scientific Sessions

The session topics for Scientific Program are Peptides in the Clinic, Drug Delivery, Chemistry of Complex Peptides, Spotlight on Discovery, and Peptide Showcase. Abstracts may be submitted via the Apply to Present page on the website. Submissions will be reviewed by the Scientific Advisory Board on a monthly basis and the speaker will be notified of a decision.

Presentation length: Format is 25-30 minutes slide presentation with 5-10 minutes for Q&A, with the exception of Peptide Showcase talks which are 10 minute slide presentations with 5 minutes for Q&A. Please confirm with your session chair to confirm the exact presentation length.

Invited Speakers: Speakers are requested to supply their presentation details 30 days after receiving an invitation to present.

Program Book Deadline: Final abstract and title must be provided no later than September 1st. No changes to the program are possible after this date.

Presentation Format: Oral presenters please provide your presentation slides to the A/V table on the day of your presentation.

Lodging: All speakers are requested to reserve their own room. Discount rates at the conference hotel are available until August 16th.

Registration: All speakers, excluding sponsored presentation speakers, receive a complimentary registration upon approval of the abstract.

Peptide Showcase Description

The Peptide Showcase is an opportunity for an individual or company to “showcase” new ideas, technology and pipeline assets. Priority shall be given to presentations from biotech and startup companies. Service providers and vendors are not eligible. Speakers in the session receive a complimentary event registration.

Posters

Posters can be presented on any topic relevant to peptides including original research, innovative products and technologies.

Eligibility- Any attendee (from academia, industry, biotech or vendor/sponsor) can present a poster. The presentation must contain original scientific thinking. To submit a poster go to the Submit a Poster link from the meeting menu. All submissions are reviewed on a rolling basis and will be notified of approval. September 1st is the last day to submit a poster abstract. Approved posters are published on the BPF website.

A 30 ” x 40″ board shall be provided with thumb tacks. Board will be on an easel and can be rotated for either landscape or portrait formats. Once you apply for a poster, you will get email confirmation that your poster was accepted. The poster session and number assignments will be emailed one week before the Symposium.

Poster boards shall be available for display from 8am to 8pm the day of your assigned poster session. See the program agenda for the poster session schedule.

Public Release

Every presentation at the Boulder Peptide Symposium is automatically recorded. Speakers are required to give consent for sharing of the presentation video with the peptide community.